Current cancer drug targets最新文献

{"title":"YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas.","authors":"Miao Wang, Siyu Qian, Yue Zhang, Qingjiang Chen, Xudong Zhang, Mingzhi Zhang","doi":"10.2174/0115680096328745250122231110","DOIUrl":"https://doi.org/10.2174/0115680096328745250122231110","url":null,"abstract":"<p><strong>Introduction: </strong>Yippee Like 1 (YPEL1) is a nuclear protein involved in various cellular processes, including cell cycle regulation, senescence, and mammalian develop-ment. It plays a dual role in cancer, functioning as either an antitumor or tumor-promoting factor.</p><p><strong>Methods: </strong>In the current study, via The Cancer Genome Atlas (TCGA) search, we found that YPEL1 is aberrantly expressed in various cancers. High expression of YPEL1 corre-lated with poorer survival outcomes, whereas low expression of YPEL1 was associated with improved overall survival of patients. YT cell lines and gemcitabine-resistant YT cell line (YT/Gem-R) exhibit elevated levels of the YPEL1 protein.</p><p><strong>Result: </strong>Furthermore, we determined that knocking down YPEL1 in both YT cell and YT/Gem-R induces apoptosis and autophagy. Additionally, silencing YPEL1 significantly reduced the tumor growth the xenograft model.</p><p><strong>Conclusion: </strong>These findings suggest that YPEL1 exhibits the potential for being used as a target for NK / T cell lymphoma treatment.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Nanomaterials for Targeted Drug Delivery: Emerging Trends and Future Prospects in Nanodrug Development.","authors":"Abdulrahman Al Ayidh, Mohamed Abbas, Muneer Parayangat, Thafasal Ijyas","doi":"10.2174/0115680096362452250301054711","DOIUrl":"https://doi.org/10.2174/0115680096362452250301054711","url":null,"abstract":"<p><p>The development of targeted drug delivery systems has transformed modern medicine, offering novel approaches to improve the efficacy and safety of therapeutic agents. Nanomaterials, due to their unique physicochemical properties, have emerged as pivotal contributors to this transformation. This paper aimed to explore recent advance-ments in nanomaterials for targeted drug delivery, highlighting emerging trends and pro-spects in nanodrug development. Nanomaterials, including polymers, liposomes, metal-based nanoparticles, dendrimers, and carbon-based structures, possess high surface area, tunable surface chemistry, and biocompatibility, which enable precise drug delivery, en-hanced solubility, improved stability, and controlled release profiles. These characteristics allow for the targeting of specific tissues or cells, thereby maximizing therapeutic efficacy while minimizing systemic side effects. The objective of this review was to provide a comprehensive analysis of the role of these nanomaterials in improving drug bioavailabil-ity, targeting specificity, and controlled release, with particular emphasis on their applica-tions in cancer therapy, antibiotic delivery, and gene therapy. This paper addresses critical challenges associated with the use of nanomaterials, including toxicity, potential immuno-genicity, regulatory hurdles, and the complexities involved in large-scale manufacturing and clinical translation. Strategies to overcome these barriers, such as surface modifica-tion, optimization of nanomaterial properties, and the development of multifunctional and smart nanocarriers, are discussed. The review concludes by emphasizing the potential of nanomaterials to revolutionize drug delivery systems, contributing to the development of more effective, personalized, and patient-friendly therapeutic options, thereby paving the way for next-generation treatments for a wide range of diseases.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143613844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EWS-RNA Binding Protein 1: Structural Insights into Ewing Sarcoma by Conformational Dynamics Investigations.","authors":"Saba Shahzadi, Muhammad Yasir, Andrzej Kloczkowski, Mubashir Hassan","doi":"10.2174/0115680096330765250220053705","DOIUrl":"https://doi.org/10.2174/0115680096330765250220053705","url":null,"abstract":"<p><strong>Background: </strong>Prior research has demonstrated that proteins play a significant role in the prognosis and treatments of various sarcomas, including Ewing sarcoma through the interplay of downstream signaling cascades. However, there is limited understanding about the strcucture conformation of EWSR1 and its structural implication in the prognosis of Ews-ing Sarcoma by interaction with RNA molecules.</p><p><strong>Aims: </strong>The primary goal of ongoing research is to determine how EWSR1 contributes to Ewing sarcoma.</p><p><strong>Objective: </strong>The current study explores the complexity of EWSR1 structure and its conforma-tional interactions with RNA in relation to Ewing sarcoma.</p><p><strong>Methods: </strong>Here, we employed a comparative modeling approach to predict EWSR1 domains separately and assembled them into one structural unit using a DEMO server. Additionally, the RNA motifs interacting with EWSR1 were predicted, and the 3D model was built using RNAComposer. Protein-RNA docking and MD simulation studies were carried out to check the intermolecular interactions and stability behavior of docked EWSR1-RNA complexes.</p><p><strong>Results: </strong>The overall results explore the structural insights into EWSR1 and their interactions with RNA, which may play a momentous role in co- and post-transcriptional regulation to control gene expression.</p><p><strong>Conclusion: </strong>Taken togather, our findings suggest that EWSR1 may be a useful therapeutic target for the diagnosis and management of Ewing sarcoma.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Radiation Therapy Enhancement and Radio-Protection By Nano-Curcumins: A Systematic Review.","authors":"Elham Raeisi, Saeid Heidari-Soureshjani, Catherine Mt Sherwin, Yves Lemoigne, Hossein Mardani -Nafchi","doi":"10.2174/0115680096360434250211042759","DOIUrl":"https://doi.org/10.2174/0115680096360434250211042759","url":null,"abstract":"<p><strong>Introduction/objective: </strong>Nano-curcumins (Nano-CUR) improve solubility, bio-availability, and stability of the release of CUR into the body. In this systematic review, we aim to investigate different CUR nanoformulations' in targeting radiosensitizing path-ways and radioprotective mechanisms.</p><p><strong>Methods: </strong>We thoroughly searched electronic databases, including PubMed/MEDLINE, Web of Science, Scopus, Embase, and Cochrane Library to identify pertinent studies pub-lished before July 21, 2024. inclusion and exclusion criteria were set based on the study's purposes. Two reviewers independently performed data extraction to ensure precision and minimize bias. Subsequently, the data were extracted and analyzed.</p><p><strong>Results: </strong>A total of 24 articles were included. Nano-CURs by scavenging the levels of re-active oxygen species (ROS), decrease malondialdehyde (MDA), improve superoxide dismutase (SOD), prevent DNA methylation, reduce tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-b and transforming growth factor-beta (TGF-β1), improve cell cycle, inhibit vascular endothelial growth factor (VEGF), attenuate cell cytotoxicity and modu-late cell apoptosis induce its radioprotective effects. In contrast, Nano-CUR induces oxida-tive stress and accumulation ROS, inhibits nuclear factor-κB (NF- κB), activates the ex-pression of TNF, TGF-β, phosphatidylinositol and FoxO, causing DNA damage, activat-ing proapoptotic pathways (boosted P53, P21 and BAX expressions), cell cycle arrest, re-ducing hypoxia-inducible factor (HIF-1α), revealed radiosensitizing effects.</p><p><strong>Conclusion: </strong>Nano-CURs improve CUR bioavailability and increase cancerous cells' sen-sitivity to radiation. They also protect healthy cells from ionizing radiation without signifi-cant side effects.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143584999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Competing Risk Analysis for Diabetes Mellitus Mortality in Bladder Cancer Patients: A Population-based Study.","authors":"Shunde Wang, Baishu Zheng, Junjie Yang, Junyong Zhang","doi":"10.2174/0115680096356675250217074915","DOIUrl":"https://doi.org/10.2174/0115680096356675250217074915","url":null,"abstract":"<p><strong>Background: </strong>Historically, there has been a lack of focus on the mortality rates of individuals with both diabetes and Bladder Bancer (BC). Our study aimed to identify the risk factors associated with death from Diabetes Mellitus (DM) in BC patients.</p><p><strong>Methods: </strong>Data was gathered from the SEER database on individuals who were diagnosed with BC between the years 2000 and 2017. Calculation of the Standardized Mortality Ratio (SMR) was performed to determine the mortality rate of DM in patients from BC. Potential risk factors for DM mortality were identified by a multivariate competing risk model. Haz-ard Ratios (HR), with 95% confidence intervals (95% CI) were used to indicate the degree of associated risk.</p><p><strong>Results: </strong>A total of 217,230 BC patients' data were collected from the SEER database for analysis. Among them, 98,880 patients passed away, and 1,783 patients encountered DM mortality. The overall SMR for DM mortality in BC patients was 3.32 (95% CI: 3.17-3.48). Results indicated that SMR increased with increasing years but decreased with increasing follow-up time. Multivariate competing risk analysis shows that BC patients with the fol-lowing factors were at higher risk of developing DM mortality: advanced age, male, black, in situ tumor stage, early year of diagnosis, pathology type of transitional cell carcinoma, without chemotherapy or radiation therapy, and absence of spouse (including separated, di-vorced, widowed, and unmarried).</p><p><strong>Conclusion: </strong>Individuals diagnosed with BC are at a considerably elevated risk of mortality from DM compared to the general population. It is of the utmost importance to identify high-risk groups and implement effective interventions for DM in order to enhance the sur-vival rate among this patient population.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress of M6A Methylation Modification in Immunotherapy of Colorectal Cancer.","authors":"Jingfan Zheng, Yuyu Chen, Xintong Peng, Wei Zheng, Yu Zhang, Fengrong Hei, Zhong Lu","doi":"10.2174/0115680096332984250221071109","DOIUrl":"https://doi.org/10.2174/0115680096332984250221071109","url":null,"abstract":"<p><p>Among the Poly(ADP-ribose) Polymerase (PARP) family in mammals, PARP1 is the first identified and well-studied member that plays a critical role in DNA damage repair and has been proven to be an effective target for cancer therapy. Here, we have reviewed not only the role of PARP1 in different DNA damage repair pathways, but also the working mech-anisms of several PARP inhibitors (PARPi), inhibiting Poly-ADP-ribosylation (PARylation) processing and PAR chains production to trap PARP1 on impaired DNA and inducing Tran-scription-replication Conflicts (TRCs) by inhibiting the PARP1 activity. This review has sys-tematically summarized the latest clinical application of six authorized PARPi, including olaparib, rucaparib, niraparib, talazoparib, fuzuloparib and pamiparib, in monotherapy and combination therapies with chemotherapy, radiotherapy, and immunotherapy, in different kinds of cancer. Furthermore, probable challenges in PARPi application and drug resistance mechanisms have also been discussed. Despite these challenges, further development of new PARP1 inhibitors appears promising as a valuable approach to cancer treatment.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Functions and Therapeutic Potential of UBE2T in Human Cancer.","authors":"Keshen Wang, Qichen He, Xiangyan Jiang, Yong Ma, Tao Wang, Huinian Zhou, Zeyuan Yu, Zuoyi Jiao","doi":"10.2174/0115680096370867250211070948","DOIUrl":"https://doi.org/10.2174/0115680096370867250211070948","url":null,"abstract":"<p><p>The ubiquitin-proteasome system is a fundamental regulatory mechanism that governs protein stability and intracellular signaling in eukaryotic cells. This system relies on a coordinated cascade of enzymatic activities involving activating enzymes, conjugating enzymes, and ligases to assemble distinct ubiquitin signals. These signals are subsequently edited, removed, or interpreted by deubiquitinases and ubiquitin-binding proteins. While E3 ligases have traditionally been recognized as the primary determinants of substrate specificity in the ubiquitination process, recent studies have revealed that the dysregulation of E2 enzymes can also lead to significant pathological outcomes, including chromatin instability, immune dysregulation, metabolic dysfunction, and an elevated risk of cancer. Consequently, E2 enzymes have emerged as promising therapeutic targets for the treatment of various dis-eases. This review provides a comprehensive examination of the roles and mechanisms of the ubiquitin-conjugating enzyme E2T (UBE2T) in cancer initiation, progression, and therapy resistance, highlighting its potential as a compelling target for cancer therapeutics.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Immunotherapies: Navigating the Immune Landscape.","authors":"Rakesh Kumar, Joseph Finian Maleme, Shubham Kumar, Kalvatala Sudhakar, Darshan R Telange, Oshin Maiti, Pratibha Sahoo, Alaa A A Aljabali, Vijay Mishra, Yachana Mishra","doi":"10.2174/0115680096346735250218110708","DOIUrl":"https://doi.org/10.2174/0115680096346735250218110708","url":null,"abstract":"<p><p>Biotechnology has paved the way for the development of cancer therapeutics that harness biological systems. Cancer immunotherapy (CI) is a pivotal and swiftly progressing therapeutic modality, alongside surgical intervention, cytotoxic chemo-therapy, radiation therapy, and targeted therapy. Therefore, this is the fifth cornerstone of cancer management. Biotechnological pharmaceuticals are superior modalities for combat-ing neoplastic conditions when juxtaposed with conventional chemical therapeutics. Consid-ering empirical evidence, it can be posited that biotechnology exhibits a heightened level of precision in targeting malignant cells associated with cancer, thereby minimizing collateral damage compared to conventional chemotherapeutic approaches. Furthermore, this ap-proach harnesses the inherent capabilities of the immune system to impede cancer recur-rence, thereby facilitating a more proactive therapeutic intervention, as opposed to a mere deleterious remedy. Novel cancer immunotherapeutic medications, along with uncomplicat-ed methodologies that enable the quantitative evaluation of the effectiveness of compounds capable of modifying T cell-mediated, tumor antigen-specific immune responses, play a pivotal role in the assessment process. This highlights the considerable promise of immuno-therapies, monoclonal antibodies, and an array of biotechnological products in a relentless battle against cancer.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological Evaluation of Amorphophalli rhizoma to Inhibit the Progression of Estrogen Receptor+ (ER+) Breast Cancer by Modulating the PI3K/AKT Cell Signaling Pathway.","authors":"Hailong Li, Qinghong Yu, Jiaqing Song, Haining Ding, Yian Chen, Ying Jin, Hongting Wu, Liaqat Hussain, Xiufei Gao","doi":"10.2174/0115680096360994250106082347","DOIUrl":"https://doi.org/10.2174/0115680096360994250106082347","url":null,"abstract":"<p><strong>Introduction: </strong>Breast Cancer (BC) is one of the most prevalent malignant tumors in women. The incidence of estrogen receptor-positive (ER+) breast cancer is as high as 70%, and it is increasing. Amorphophalli rhizoma (APR) has the potential to be used in breast cancer.</p><p><strong>Aims: </strong>The objectives of the present study were to explore the impact of different APR extracts on the proliferation, migration, and invasion of ER+BC and to investigate their possible mechanism at the molecular level.</p><p><strong>Methods: </strong>Various extracts of APR were prepared in different solvents, such as petroleum ether, ethyl acetate, n-butanol, and water. ER+ T47D breast cancer cell lines were acquired and uti-lized to assess the effect of APR extracts on ER+ BC. Cell viability was assessed using the cell counting kit8 (CCk8) method, while anti-invasive and migratory effects were examined by transwell and wound healing assay. All the extracts were initially screened, and the ethyl acetate fraction (APR-EA) was found to be the most effective. Ultra High-Performance Liquid Chro-matography (UHPLC) of APR-EAE extract revealed the presence of various phytochemicals, such as succinic acid, 2-methoxy resorcinol, penicillic acid, morphine, salicylic acid, α-linolenic acid, and linolenic acid. Flow cytometry, western blot, and immunohistochemistry were used to explore molecular mechanisms.</p><p><strong>Results: </strong>APR-EA demonstrated anti-proliferative, anti-migratory, and anti-invasive effects on the ER+ T47D cell line. Thus, APR-EAE might inhibit the expression of P-PI3K/PI3K and P-Akt/Akt proteins, which subsequently represses the expression of ERα. This inhibition affects the downstream expression of the proteins CDK4 and Bcl-2, which are linked to cell growth and apoptosis.</p><p><strong>Conclusion: </strong>Additionally, APR-EA might increase the expression of P21 and Bax proteins, which are associated with cell cycle arrest and apoptosis. Overall, these effects contribute to the anti-ER+ breast cancer properties of APR-EA.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Embracing the Circular Journey of RNA in Colorectal Cancer.","authors":"AmirHosein Barjasteh, Ayat Heidar Abdolamir, Abdulridha Mohammed Al-Asady, Hanieh Latifi, Amir Avan, Majid Khazaei, Mikhail Ryzhikov, Seyed Mahdi Hassanian","doi":"10.2174/0115680096324880250117062148","DOIUrl":"https://doi.org/10.2174/0115680096324880250117062148","url":null,"abstract":"<p><p>Recent investigations have indicated that circRNAs (circular RNAs), a novel member of the Noncoding RNA family, are a crucial genetic factor in Colorectal Cancer (CRC), development. These circRNAs have a range of biological functions, including regu-lating the expression of target genes, altering protein activity, and producing proteins. Addi-tionally, circRNAs significantly affect tumor cell proliferation, aggression, migration, and cell death. CircRNAs have an essential role in carcinogenesis, metastasis, and drug toler-ance. Various signaling pathways are linked by circRNAs, providing opportunities for a more tailored chemotherapy regimen as well as early diagnosis and prognosis determination. By identifying new and potent circRNAs in signaling pathways, we can aim for them with ASO or siRNAs and provide a powerful combination therapy. In this review, we strive to summarize the biological and carcinogenic functions of circRNAs and their impact on spe-cific signaling pathways like PI3K/AKT, MAPK, Notch, JAK/STAT, Hippo/YAP, and WNT/β-catenin which lead to Epithelial-mesenchymal-transition(EMT) in CRC. Further-more, we explore the clinical significance of circRNAs and important signaling proteins in treating CRC.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}